MedTrace Logo

Treatment of Postsphincterotomy Bleeding With a Novel Self-assembling Peptide Hemostatic Gel.

NCT05886127 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-06-02

No results posted yet for this study

Summary

The aim of this observational study is to evaluate safety and efficacy of a novel self-assembling peptide hemostatic gel in reduction of bleeding after endoscopic sphincterotomy during ERCP (endoscopic retrograde cholangiopancreatography )

Conditions

  • Biliary Obstruction
  • Complication of Treatment

Interventions

DEVICE

A novel hemostatic agent (Purastat®)

A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater

Sponsors & Collaborators

  • General University Hospital, Prague

    lead OTHER

Principal Investigators

  • Petr Hrabak · General University Hospital, Prague

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-07-31
Completion
2023-10-30

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05886127 on ClinicalTrials.gov